Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018))

Egils Vjaters; Martin Bögemann; Neal D. Shore; Matthew R. Smith; Teuvo L. J. Tammela; Albertas Ulys; Sergey Polyakov; Mindaugas Jievaltas; Murilo Luz; Boris Alekseev

doi:10.1016/j.eururo.2022.11.018

Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018))

Egils Vjaters
, Martin Bögemann
, Neal D. Shore
, Matthew R. Smith
, Teuvo L. J. Tammela
, Albertas Ulys
, Sergey Polyakov
, Mindaugas Jievaltas
, Murilo Luz
, Boris Alekseev

The Faculty of Medicine and Life Sciences

Research output: Contribution to journal › Erratum

1 Citation (Scopus)

Abstract

The publisher regrets that during the typesetting of this paper, some less-than-or-equal-to signs were inadvertently reversed. This has now been corrected and will subsequently appear correctly in print. The publisher would like to apologise for any inconvenience caused.

Original language	English
Pages (from-to)	e60
Journal	European Urology
Volume	83
Issue number	2
DOIs	https://doi.org/10.1016/j.eururo.2022.11.018
Publication status	Published - Feb 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.eururo.2022.11.018

Fingerprint

Dive into the research topics of 'Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018))'. Together they form a unique fingerprint.

Cite this

Vjaters, E., Bögemann, M., D. Shore, N., R. Smith, M., L. J. Tammela, T., Ulys, A., Polyakov, S., Jievaltas, M., Luz, M., & Alekseev, B. (2023). Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018)). European Urology, 83(2), e60. https://doi.org/10.1016/j.eururo.2022.11.018

Vjaters, Egils ; Bögemann, Martin ; D. Shore, Neal et al. / Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018)). In: European Urology. 2023 ; Vol. 83, No. 2. pp. e60.

@article{8071639b8a924b4a912c566843bb771f,

title = "Erratum to {"}Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018))",

abstract = "The publisher regrets that during the typesetting of this paper, some less-than-or-equal-to signs were inadvertently reversed. This has now been corrected and will subsequently appear correctly in print. The publisher would like to apologise for any inconvenience caused.",

author = "Egils Vjaters and Martin B{\"o}gemann and \{D. Shore\}, Neal and \{R. Smith\}, Matthew and \{L. J. Tammela\}, Teuvo and Albertas Ulys and Sergey Polyakov and Mindaugas Jievaltas and Murilo Luz and Boris Alekseev",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s)",

year = "2023",

month = feb,

doi = "10.1016/j.eururo.2022.11.018",

language = "English",

volume = "83",

pages = "e60",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "2",

}

Vjaters, E, Bögemann, M, D. Shore, N, R. Smith, M, L. J. Tammela, T, Ulys, A, Polyakov, S, Jievaltas, M, Luz, M & Alekseev, B 2023, 'Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018))', European Urology, vol. 83, no. 2, pp. e60. https://doi.org/10.1016/j.eururo.2022.11.018

Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018)). / Vjaters, Egils; Bögemann, Martin; D. Shore, Neal et al.
In: European Urology, Vol. 83, No. 2, 02.2023, p. e60.

Research output: Contribution to journal › Erratum

TY - JOUR

T1 - Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018))

AU - Vjaters, Egils

AU - Bögemann, Martin

AU - D. Shore, Neal

AU - R. Smith, Matthew

AU - L. J. Tammela, Teuvo

AU - Ulys, Albertas

AU - Polyakov, Sergey

AU - Jievaltas, Mindaugas

AU - Luz, Murilo

AU - Alekseev, Boris

PY - 2023/2

Y1 - 2023/2

N2 - The publisher regrets that during the typesetting of this paper, some less-than-or-equal-to signs were inadvertently reversed. This has now been corrected and will subsequently appear correctly in print. The publisher would like to apologise for any inconvenience caused.

AB - The publisher regrets that during the typesetting of this paper, some less-than-or-equal-to signs were inadvertently reversed. This has now been corrected and will subsequently appear correctly in print. The publisher would like to apologise for any inconvenience caused.

UR - https://www.sciencedirect.com/science/article/pii/S0302283822028378

UR - https://www.scopus.com/pages/publications/85145287074

U2 - 10.1016/j.eururo.2022.11.018

DO - 10.1016/j.eururo.2022.11.018

M3 - Erratum

SN - 0302-2838

VL - 83

SP - e60

JO - European Urology

JF - European Urology

IS - 2

ER -

Vjaters E, Bögemann M, D. Shore N, R. Smith M, L. J. Tammela T, Ulys A et al. Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018)). European Urology. 2023 Feb;83(2):e60. doi: 10.1016/j.eururo.2022.11.018

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this